aTyr Pharma, Inc. (LIFE)
NASDAQ: LIFE · IEX Real-Time Price · USD
1.950
-0.050 (-2.50%)
Mar 28, 2024, 3:59 PM EDT - Market closed
aTyr Pharma Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for aTyr Pharma stock have an average target of 23.67, with a low estimate of 16 and a high estimate of 35. The average target predicts an increase of 1,113.85% from the current stock price of 1.95.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for aTyr Pharma stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
RBC Capital | RBC Capital | Buy Maintains $19 → $16 | Buy | Maintains | $19 → $16 | +720.51% | Mar 15, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +1,694.87% | Mar 15, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +1,694.87% | Feb 21, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +1,694.87% | Sep 21, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +1,694.87% | Sep 14, 2023 |
Financial Forecast
Revenue This Year
7.28M
from 353.00K
Increased by 1,962.32%
Revenue Next Year
9.55M
from 7.28M
Increased by 31.20%
EPS This Year
-0.87
from -0.94
EPS Next Year
-0.97
from -0.87
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 26.3M | 25.6M | 171.9M | 298.8M | 717.6M |
Avg | 7.3M | 9.6M | 94.7M | 200.2M | 432.7M |
Low | n/a | n/a | 26.4M | 68.9M | 195.0M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 7,336.3% | 252.3% | 1,699.7% | 215.6% | 258.5% |
Avg | 1,962.3% | 31.2% | 891.3% | 111.4% | 116.1% |
Low | - | - | 176.9% | -27.2% | -2.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.59 | -0.91 | 0.84 | 2.06 | 5.16 |
Avg | -0.87 | -0.97 | -0.18 | 0.88 | 2.88 |
Low | -0.97 | -1.01 | -0.81 | -0.18 | 1.23 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 486.0% |
Avg | - | - | - | - | 227.2% |
Low | - | - | - | - | 39.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.